- info@myglp1store.com
- +1 (904) 942-2327
- 6953 Powers avenue suite 19 Jacksonville Fl 32217
Need Any Help?
+1 (904) 942-2327
+1 (904) 942-2327
$600.00
Tirzepatide is a synthetic dual-agonist formulation associated with GLP-1 and GIP receptor signaling pathways. It is prepared under controlled conditions to ensure stable composition and reliable quality.
| Component | Description |
|---|---|
| Active Compound | Tirzepatide (synthetic dual-agonist targeting GLP-1 and GIP receptors) |
| Net Content | 120 mg per vial |
| Form | Lyophilized powder |
| Excipients | None added unless otherwise specified |
| Purity Verification | Analytical confirmation via HPLC or mass spectrometry |
Tirzepatide has well-characterized structural properties. References in scientific literature describe studies examining ligand-receptor interactions, intracellular signaling activation, and metabolic pathway modulation in controlled experimental settings. All references are provided strictly for informational purposes and do not imply dosing or human-use guidance.
This product is intended for research purposes only. It is designated strictly for in vitro testing and laboratory experimentation and is not approved for human or animal consumption. All information provided on this website is for educational and informational purposes only. This product should be handled only by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
Tirzepatide 120 mg is a dual-agonist formulation with a well-characterized molecular structure associated with GLP-1 and GIP receptor signaling. Its structure enables controlled evaluation of receptor binding kinetics, intracellular signal transduction, and downstream metabolic pathway responses.
Tirzepatide may be applied in experimental studies such as:
GLP-1 and GIP receptor binding kinetics
Intracellular signaling cascade analysis
Secondary messenger and gene expression response evaluation
Comparative dual-agonist structureāactivity relationship analysis
Stability, degradation, and formulation studies
These studies allow for mechanistic investigations into dual-incretin receptor function and associated cellular signaling networks.
Store under recommended cold conditions to maintain stability. Handle using standard laboratory protocols. Preparation, aliquoting, and storage should follow institutional guidelines.
This formulation is provided for experimental and informational purposes only.Ā No physiological, medical, or performance outcomes are implied or guaranteed. Users are responsible for institutional and regulatory compliance when handling this compound.
Tirzepatide is a synthetic dual-agonist formulation associated with GLP-1 and GIP receptor signaling pathways. It is prepared under controlled conditions to ensure stable composition and reliable quality.
| Component | Description |
|---|---|
| Active Compound | Tirzepatide (synthetic dual-agonist targeting GLP-1 and GIP receptors) |
| Net Content | 120 mg per vial |
| Form | Lyophilized powder |
| Excipients | None added unless otherwise specified |
| Purity Verification | Analytical confirmation via HPLC or mass spectrometry |
Tirzepatide has well-characterized structural properties. References in scientific literature describe studies examining ligand-receptor interactions, intracellular signaling activation, and metabolic pathway modulation in controlled experimental settings. All references are provided strictly for informational purposes and do not imply dosing or human-use guidance.
Reviews
There are no reviews yet.